LoadingLoadingLoadingNet selling: insiders sold $36.5M and bought $0 on the open market in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsEach bar is 100% of that source’s money. The notch marks an even split.
Lean is the direction of the latest moves. Descriptive, not advice.
Buys/Adds (2)
Bank of America
$108.0M
added
FMR LLC
$19.8M
added
Sells/Trims (1)
Citadel
$66.1M
trimmed
Sells (3)
Warren Buffett
$36.5M
sold
Rodriguez Javier
$14.5M
sold
Waters Kathleen Alyce
$3.2M
sold
Buys (1)
Sells (1)
No tracked top-trader positions in DVA as of Oct 24, 10:57 UTC.
Hyperliquid positioning - not every stock is covered
Last report
Aug 4, 2026
Period ending
Jun 30, 2026
Earnings per share
$4.01 expected
Revenue
Financial statements: Alpha Vantage
Estimates as of Oct 23, 2026
EPS expected
$3.39 to $4.02
Revenue expected
6 analysts
Last 30 days
Analysts cutting estimates
Estimate drift
Change in 30 days
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / income | Surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 4, 2026 | $4.02 / $4.01Alpha Vantage | +0.25% in line | $3.55B No estimate | Unavailable |
| Mar 31, 2026 | May 5, 2026 | $2.87 / $2.33Alpha Vantage | +23.18% beat | $3.42B No estimate | Unavailable |
| Dec 31, 2025 | Feb 2, 2026 | $3.40 / $3.19Alpha Vantage | +6.58% beat | $3.62B No estimate | Unavailable |
| Sep 30, 2025 | Oct 29, 2025 | $2.51 / $3.17Alpha Vantage | -20.82% miss | $3.42B No estimate | Unavailable |
| Jun 30, 2025 | Aug 5, 2025 | $2.95 / $2.75Alpha Vantage | +7.27% beat | $3.38B No estimate | Unavailable |
| Mar 31, 2025 | May 12, 2025 | $2.00 / $2.02Alpha Vantage | -0.99% in line | $3.22B No estimate | Unavailable |
| Dec 31, 2024 | Feb 13, 2025 | $2.24 / $2.13Alpha Vantage | +5.16% beat | $3.29B No estimate | Unavailable |
| Sep 30, 2024 | Oct 29, 2024 | $2.59 / $2.72Alpha Vantage | -4.78% miss | $3.26B No estimate | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue and income use company releases, SEC filings, Alpha Vantage or Yahoo Finance. Non-USD revenue carries its currency code. Comparisons require a paired release estimate.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.42B | $3.62B | $3.42B | $3.55B |
| Cost of what it sold | $2.33B | $2.60B | $2.34B | $2.39B |
| Gross profit | $1.09B | $1.02B | $1.07B | $1.16B |
| What it spent | ||||
| Sales and admin | $414.4M | $472.4M | $421.9M | $423.5M |
| Other operating costs | $167.3M | — | $169.5M | $167.8M |
| Total operating expenses | $581.7M | $472.4M | $591.4M | $591.3M |
| What was left | ||||
| Operating profit | $505.8M | $551.2M | $481.9M | $570.8M |
| Interest on debt | $150.6M | $118.0M | $145.1M | $146.4M |
| Profit before tax | $308.8M | $382.8M | $341.2M | $435.0M |
| Tax | $68.6M | $76.7M | $66.2M | $91.8M |
| Net profit | $150.3M | $234.2M | $197.5M | $265.4M |
| EBITDA | $636.9M | $717.7M | $655.2M | $753.1M |
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage is bullish
DaVita agrees to $15M settlement in data breach lawsuit after cyberattack
BearishOct 21Dialysis treatment moves one step closer to a natural kidney as DaVita rolls out an innovation.
Leans bullishOct 20Why DaVita (DVA) Stock Is Nosediving
BearishOct 20Why DaVita (DVA) Stock Is Nosediving
BearishOct 20Wall Street Zen upgrades DaVita stock to Buy
BullishOct 20JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17
NeutralOct 20DaVita, Fresenius drop as RFK Jr. is said to plan dialysis market reforms
BearishOct 20Pediatrix Medical Group, Inc. (MD) Stock forecasts
BullishOct 20
